Angion Biomedica Corp


Welcome to Angion Biomedica! We are a biopharmaceutical company established in 1998 to discover and develop novel therapeutic agents to treat acute and chronic organ injury by harnessing the body’s protective, reparative and regenerative systems. The therapeutic strategy we follow and pathways we target were selected to prevent or limit acute injury, and to prevent or limit acute injury from evolving into chronic disease. These pathways also have the potential to stabilize, and even reverse, chronic disease. We believe these treatment objectives address significant unmet medical need. Our clinical programs are currently focused on renal transplantation, acute kidney disease and acute cardiac disease.

Angion's Science

Our discovery and development efforts have yielded a rich and diverse product pipeline comprising novel, small molecules with HGF-like cellular activity, orally bioavailable receptor tyrosine kinase inhibitors and cytochrome P450-26 (CYP26) inhibitors that are in clinical or preclinical development. We also have discovery programs on inhibitors of other CYP enzymes, a relaxin peptide delivery platform and synthetic compounds with relaxin-like activity and other fibrosis related targets.

What's new
  • Angion Biomedica Corp. Advances BB3 into Pivotal Phase 3 Clinical Trial in Renal Transplant Patients with Delayed Graft Function.
  • Angion’s novel CYP26 inhibitor ANG-3522 licensed to Ohr Cosmetics, LLC, ameliorates skin conditions in subjects with ichthyosis after 28 days of topical treatment.
  • Angion’s first-in-class small molecule with HGF-like activity enters Phase II clinical trials for renal and cardiac indications.
  • Angion relocates to fully integrated facility in Uniondale, NY.
  • Angion Enters Multi-Institutional Alliance to Advance Novel and Promising Therapies for Ischemic Stroke.
  • Angion's drug BB3 receives both Fast Track and Orphan Drug designations from FDA.

More info

More info

More info

Terms of usePrivacy statementSitemapFor Employees Only
Copyright © 2012 Angion Biomedica Corp. All Rights Reserved.
Home | Company | Pipeline | Science | Careers | Contact Us | Clinical Trials